

Letter to the editor

Enhancing the diagnostic and management approaches for ST Elevation Myocardial Infarction

Siddhi Patel*

Author's Affiliations

*MBBS student, III Year part 2, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Pimpri, Pune, India

Correspondence to:

Siddhi Patel
Dr. D. Y. Patil Medical College, Hospital and Research Centre, Pimpri, Pune, India

Keywords: Diagnosis, Management, ST Elevation, Myocardial infarction

Dear Editor,

According to current research, there have been a number of significant developments as well as continuous difficulties in the diagnosis and treatment of ST-elevation myocardial infarction (STEMI). There are still areas where we can enhance current techniques to improve patient outcomes, even with tremendous advances.

The significant benefits of prompt intervention in STEMI management are highlighted by recent research. As per the 2020 guidelines of the European Society of Cardiology (ESC), prompt primary percutaneous coronary intervention (PCI) is crucial in mitigating mortality and enhancing prognoses among patients with STEMI [1]. The SWEDEHEART registry, which records improved outcomes in patients with STEMI over the past 20 years due to the adoption of evidence-based treatments, attests to the significant improvements in patient outcomes that have resulted from the implementation of these guidelines [2].

But there are still a lot of obstacles to overcome. The length of time it takes to start treating symptoms is a significant worry. A recent review revealed a paradox in the efficacy of the STEMI network: while treatment methods have improved, there have been alarming trends observed in the total ischemia time and one-year deaths [3].

This emphasizes the need for more potent tactics to reduce treatment setbacks.

High-sensitivity cardiac troponin assays have proven to be essential in the timely detection of myocardial infarction. Research has demonstrated that, as compared to conventional assays, high sensitivity cardiac troponin I (hs-cTnI) assays provide better diagnostic performance [4]. These assays provide early, precise diagnosis and timely treatment initiation. However, ongoing assessment of these tests is still necessary to make sure they satisfy the changing requirements of clinical practice [5].

Paying attention to gender differences in STEMI management is also necessary. Studies show that relative to men, women are frequently underrepresented in clinical trials and may face treatment delays [6, 7]. For all patients to receive equitable care and see improved outcomes, these gaps must be addressed.

One exciting area of research is the incorporation of personalized medicine into STEMI therapy. Personalized methods that are adapted to each patient's unique genetic and biochemical profile may increase the efficacy of treatment plans [8].

Additionally, advancements in technology such as remote monitoring and telemedicine have the potential to transform STEMI management. The use of digital health tools can facilitate quicker diagnosis and treatment initiation, particularly in underserved or remote areas. Recent studies have demonstrated that remote ECG monitoring and telemedicine consultations can significantly reduce time to treatment and improve patient outcomes [9]. Expanding the use of these technologies could help bridge

gaps in care and further enhance the efficacy of STEMI management.

In summary, even though a lot of progress has been made in the treatment of STEMI, problems such treatment delays, gender differences, and the requirement for individualized methods still exist. To solve these problems and enhance patient outcomes, more research and the modification of therapeutic procedures in light of new information will be required.

REFERENCES

1. Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). *European heart journal* 2021;42(14):1289–367.
2. Szummer K, Wallentin L, Lindhagen L, Alfredsson J, Erlinge D, Held C, et al. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995–2014. *European heart journal* 2017;38(41):3056–65.
3. Kawecki D, Morawiec B, Gąsior M, Wilczek K, Nowalany-Kozielska E, Gierlotka M. Annual trends in total ischemic time and one-year fatalities: the paradox of STEMI network performance assessment. *Journal of clinical medicine* 2019;8(1):78.
4. Rubini Gimenez M, Twerenbold R, Reichlin T, Wildi K, Haaf P, Schaefer M, et al. Direct comparison of high-sensitivity-cardiac troponin I vs. T for the early diagnosis of acute myocardial infarction. *European heart journal* 2014;35(34):2303–11.
5. Westwood M, Ramaekers B, Grimm S, Worthy G, Fayter D, Armstrong N, et al. High-sensitivity troponin assays for early rule-out of acute myocardial infarction in people with acute chest pain: a systematic review and economic

- evaluation. *Health Technology Assessment (Winchester, England)* 2021;25(33):1.
6. Bugiardini R, Merz CNB. Angina with “normal” coronary arteries: a changing philosophy. *Jama* 2005;293(4):477-84.
 7. Alabas OA, Gale CP, Hall M, Rutherford MJ, Szummer K, Lawesson SS, et al. Sex differences in treatments, relative survival, and excess mortality following acute myocardial infarction: national cohort study using the SWEDEHEART registry. *Journal of the American Heart Association* 2017;6(12):e007123.
 8. Tada H, Fujino N, Nomura A, Nakanishi C, Hayashi K, Takamura M, et al. Personalized medicine for cardiovascular diseases. *Journal of Human Genetics* 2021;66(1):67-74.
 9. Lovell NH, De Luca V, Zhang Y, et al. Remote Monitoring of cardiac patients: current state and future directions. *Health Informatics J* 2023;29(1):47-61